PARP Inhibitors Pipeline Summary

DelveInsight’s, “PARP Inhibitors Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in PARP Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

PARP Inhibitors Understanding

PARP Inhibitors Overview

PARP inhibitors are a targeted therapy treatment for some forms of cancers that involve changes (mutations) in the BRCA gene. This includes some types of breast, ovarian and prostate cancers. They prevent cancer cells from accessing a protein the cancer can use to spread, called PARP. PARP inhibitors are especially effective at treating cancers with gene mutations that negatively affect DNA repair, such as BRCA gene mutations. Because the cancer cells have these defects, they depend more on PARP to help repair damaged DNA.

PARP inhibitors are small-molecule drugs that inhibit the DNA repair enzyme Poly(ADP-ribose) polymerase (PARP). Structurally, they usually contain a nicotinamide-like core that mimics the natural substrate Nicotinamide adenine dinucleotide (NAD⁺), allowing them to bind to the catalytic site of the enzyme. Their structures often include aromatic and heterocyclic rings that improve binding and stability within the enzyme pocket. Examples such as Olaparib and Niraparib share this common structural scaffold but differ in their side chains.

PARP inhibitors act by blocking the activity of the DNA repair enzyme Poly(ADP-ribose) polymerase (PARP), which normally repairs single-strand DNA breaks through the base excision repair pathway. When PARP is inhibited, these single-strand breaks accumulate and are converted into double-strand breaks during DNA replication. In cells with defective homologous recombination repair, such as those with mutations in BRCA1 or BRCA2, the damage cannot be properly repaired. This leads to genomic instability and ultimately causes cancer cell death, a concept known as synthetic lethality.

The off-target effects of PARP inhibitors occur when these drugs interact with proteins other than their intended target, the enzyme Poly(ADP-ribose) polymerase (PARP). One common off-target effect is lack of selectivity within the PARP family, where inhibitors also affect related enzymes such as PARP2, PARP3, or even PARP16, leading to broader biological responses.

PARP inhibitors have several therapeutic applications due to their ability to inhibit the DNA repair enzyme Poly(ADP-ribose) polymerase (PARP), leading to accumulation of DNA damage in cancer cells with defective repair mechanisms.

Cancer therapy: Used to treat cancers with mutations in BRCA1 and BRCA2 by inducing synthetic lethality and selective cancer cell death.

Ovarian cancer: Drugs such as Olaparib and Niraparib are used as treatment and maintenance therapy in advanced ovarian cancer.

Breast cancer: PARP inhibitors are used for HER2-negative metastatic breast cancer associated with BRCA mutations.

"PARP Inhibitors Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the PARP Inhibitors pipeline landscape is provided which includes the overview and PARP Inhibitors mechanism of action. The assessment part of the report embraces, in depth PARP Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PARP Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest PARP inhibitors pipeline insights, emerging therapies, and clinical advancements shaping the future of cancer treatment in 2026.

PARP inhibitors pipeline Report Highlights

The PARP inhibitors companies and academics are working to assess challenges and seek opportunities that could influence PARP Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve PARP Inhibitors.

PARP Inhibitors Emerging Drugs Analysis

This segment of the PARP Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PARP Inhibitors Emerging Drugs

Saruparib: AstraZeneca

Saruparib (AZD5305) is a next-generation, highly selective PARP1 inhibitor being developed by AstraZeneca for the treatment of homologous recombination repair (HRR)-deficient cancers, including breast, ovarian, pancreatic, and prostate cancers. Unlike earlier PARP inhibitors, saruparib selectively targets PARP1 while sparing PARP2, with the goal of improving tolerability and reducing hematologic toxicities commonly associated with this drug class.

The therapy has shown encouraging antitumor activity and a favorable safety profile in the ongoing Phase I/II PETRA study, particularly among patients with BRCA1/2, PALB2, and RAD51 mutations. Early clinical findings demonstrated durable responses and lower rates of treatment discontinuation or dose reduction compared with currently available PARP inhibitors. Saruparib is currently being evaluated across multiple late-stage and combination studies in advanced solid tumors, including metastatic prostate cancer and HR-positive/HER2-negative breast cancer, positioning it as a potentially differentiated PARP therapy within AstraZeneca’s expanding oncology pipeline.

Itareparib NMS-293: Nerviano Medical Sciences

Itareparib is a potent, highly selective PARP1 inhibitor designed to avoid trapping, a known cause of toxicity in healthy cells, making it ideal for combination with DNA-damaging agents like chemotherapies or ADC payloads. Combination dosing is the key for the PARP field to move beyond BRCA mutations. Itareparib is currently in Phase II in relapsed glioblastoma, IDH wild type study, in combination with temozolomide. Initial safety data across the program showed high bone marrow tolerability paving the way for future combinations in other tumors. NMS is developing Itareparib in GBM, astrocytoma, small cell lung cancer and non-BRCA mutation ovarian cancer.

IDX-1197: Idience Co., Ltd

IDX-1197 is an investigational novel PARP inhibitor, small-molecule therapy being developed by Idience Co., Ltd. for the treatment of advanced solid tumors. The candidate is designed to selectively target cancer-associated molecular pathways involved in tumor growth and survival, with a focus on improving antitumor efficacy while maintaining a manageable safety profile. Preclinical studies have demonstrated promising anticancer activity across multiple tumor models, supporting its advancement into early-stage clinical development. Idience is positioning IDX-1197 as part of its precision oncology pipeline aimed at addressing unmet needs in patients with treatment-resistant cancers. The program remains in the clinical development stage, with ongoing research focused on evaluating its pharmacokinetics, safety, tolerability, and therapeutic potential both as a monotherapy and in combination treatment settings. Currently in Phase I/II stage of its development for advanced solid tumors.

Further product details are provided in the report……..

PARP Inhibitors Drug Therapeutic Assessment

This segment of the report provides insights about the different PARP Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major PARP Inhibitors Players in PARP Inhibitors

There are approx. 20+ key companies which are developing the therapies for PARP Inhibitors. The companies which have their PARP Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca

PARP Inhibitors Clinical Trial Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

PARP Inhibitors Drug Route of Administration

PARP Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

PARP Inhibitors Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

PARP Inhibitors Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PARP Inhibitors Clinical Trial Activities

The PARP Inhibitors pipeline report provides insights into different PARP Inhibitors clinical trials within phase II, I, preclinical and discovery stage. It also analyses PARP Inhibitors therapeutic drugs key players involved in developing key drugs.

PARP Inhibitors Pipeline Development Activities

The PARP Inhibitors clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PARP Inhibitors drugs.

PARP Inhibitors Pipeline Report Insights

• PARP Inhibitors Pipeline Analysis
• PARP Inhibitors Therapeutic Assessment
• PARP Inhibitors Unmet Needs
• Impact of PARP Inhibitors Drugs

PARP Inhibitors Pipeline Report Assessment

• PARP Inhibitors Pipeline Product Profiles
• PARP Inhibitors Therapeutic Assessment
• PARP Inhibitors Pipeline Assessment
• PARP Inhibitors Inactive drugs assessment
• PARP Inhibitors Market Unmet Needs

Discover actionable insights into the PARP inhibitors market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The PARP Inhibitors Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing PARP Inhibitors drugs?
• How many PARP Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PARP Inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PARP Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for PARP Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

PARP Inhibitors Key Players

• AstraZeneca
• Panbela Therapeutics, Inc
• Nerviano Medical Sciences
• SciBrunch Therapeutics
• Idience Co., Ltd
• MOMA Therapeuics
• Allarity Therapeutics, Inc
• Synnovation Therapeutics

PARP Inhibitors Key Products

• Saruparib
• SBP-101
• NMS-293
• SRP-1020
• IDX-1197
• MOMA-989
• Stenoparib
• Temozolomide
• SNV1521

Explore comprehensive insights into PARP Inhibitors epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.